Skip to main content
. 2012 Sep 25;21(2):348–357. doi: 10.1038/mt.2012.204

Figure 6.

Figure 6

Neither efficacy nor toxicity observed following treatment with BCG or Coley's toxin in combination with systemic VSV. (a) Survival (tumor <1.0 cm in any diameter) of C57BL/6 mice (n = 7/group) bearing subcutaneous tumors after treatment with intravenous (IV) VSV-Δ51 (5 × 106 PFU/100 µl) or PBS (100 µl) followed by intratumoral (IT) PBS (50 µl) or BCG (1 mg/50 µl) 6 hours later. Injections started on day 7 and continued every other day for a total of four (days 7, 9, 11, 13). (b) Survival (as in a) after treatment with IV VSV-Δ51 (5 × 106 PFU/100 µl) or PBS (100 µl) followed by IT PBS (50 µl) or Coley's toxin (final dilution of 0.05 Coley's toxin in 50 µl PBS) 6 hours later. Injections started on day 7 and continued every other day for a total of four (days 7, 9, 11, 13). BCG, bacillus Calmette–Guérin; PBS, phosphate-buffered saline; PFU, plaque-forming unit; VSV, vesicular stomatitis virus.